ArticleNature communications2022

Addressing challenges with real-world synthetic control arms to demonstrate the comparative effectiveness of Pralsetinib in non-small cell lung cancer.

Sanjay Popat et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.